Analyst
HC Wainwright & Co.
Equibles does not estimate personal net worth.
Ram Selvaraju is recorded as Analyst at HC Wainwright & Co.. Ram Selvaraju has spoken on 5 earnings calls across 5 companies, most recently for Emergent BioSolutions Inc. on November 2, 2026. Those appearances were for Emergent BioSolutions Inc. (EBS), Vanda Pharmaceuticals Inc. (VNDA), Protalix BioTherapeutics, Inc. (PLX), UroGen Pharma Ltd. (URGN) and Longeveron Inc. (LGVN). The companies whose calls Ram Selvaraju spoke on are classified in the Healthcare sector.
“I was just wondering if you could provide us with some additional granularity regarding the underlying market dynamics in the Narcan market segment, Particularly as this pertains to the current state of the competitive landscape, as well as drivers of underlying market demand, particularly with respect to, as I think…”
“I just wanted to ask in particular about how quickly you expect QMILSA launch to be effected, assuming timely approval on December 12th.”
“I wanted to ask if you could comment on the core determinants of the cadence with which you expect to receive revenue from Chiesi regarding El Fabrio sales and what you think the likelihood is, if any, of increases to the full-year 2026 guidance for El Fabrio-related royalty-based revenue.”
“Thanks so much for taking my questions, and congratulations on all the progress this quarter. I just wanted to drill down on the prescribers and repeat prescribers for a second.”
“Firstly, I wanted to ask a couple of clarificatory questions regarding your activities in rare cardiological conditions.”
HC Wainwright & Co.
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
URGN
Biotechnology · Healthcare
LGVN
Biotechnology · Healthcare
